Long-term follow-up of systemic onset juvenile idiopathic arthritis patients treated with Anakinra
نویسندگان
چکیده
Results The mean follow-up was 4.02 year (range 1.05 6.16). At the last follow-up 13 patients were complete responders, 5 partial responders and 16 non responder. Among complete responders, 4 patients withdrawn Anakinra without relapses after a mean of 3 years of treatment, 7 are in remission using anakinra only, 2 patients were switched to anti IL-1 monoclonal antibody with a full response. Despite the good control of their disease 11/13 displayed at least one relapse of their disease during the follow-up with a total of 22 relapses (range 1-4 for patient). Among partial responders two patients were previously considered as complete responders. In 16 non responders patients subsequent treatments were canakinumab (1 pt), tocilizumab (5 patients), or combined immunosuppressive treatment and/or anti-TNF (10 pts). Two non-responders patients died. Responders patients confimed to have an higher number of active joints at baseline (p = 0.006) and higher WBC and neutrhophils count (p = 0.002). Newly enrolled responder patients has a significantly shorter disease duration in respect to non responder patients (p = 0.03).
منابع مشابه
Fatal myocarditis in a child with systemic onset juvenile idiopathic arthritis during treatment with an interleukin 1 receptor antagonist
BACKGROUND The pathologic diagnosis of isolated myocarditis without pericardial involvement is uncommonly encountered in systemic onset Juvenile Idiopathic Arthritis (soJIA). CASE An eleven year-old boy with soJIA died suddenly while being treated with the interleukin 1 (IL-1) receptor inhibitor, anakinra. His autopsy revealed an enlarged heart and microscopic findings were consistent with my...
متن کاملR202Q Mutation of Mediterranean Fever Gene in Iranian patients with Systemic-onset Juvenile Idiopathic Arthritis
Background: Systemic-onset Juvenile Idiopathic Arthritis (SoJIA) is an autoinflammatory disease with complex genetic trait starts in children less than 16 years of age with fever and cutaneous rash. Despite, the main genetic factors that may play a role in SoJIA have not yet been identified. High level of interleukin-1beta in the blood of SoJIA patients has been reported. The production and sec...
متن کاملThe use of tocilizumab in a child with systemic onset juvenile idiopathic arthritis and ganglioneuroblastoma
We report a case of a 6 year old girl with systemic onset juvenile idiopathic arthritis which presented at age of 3 years refractory to disease-modifying antirheumatic drugs and anakinra. During the first hospitalization a ganglioneuroblastoma (GNB) was diagnosed and consequently treated. During the SFOP treatment protocol for GNB our patient continued with low grade fever, but soon after the t...
متن کاملInterleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
BACKGROUND Anakinra treatment has been reported to be effective in some patients with systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease (AoSD). OBJECTIVES To assess the efficacy and the safety of anakinra treatment in SoJIA and AoSD. METHODS SoJIA and AoSD patients were treated with anakinra (1-2 mg/kg/day in children, 100 mg/day in adults); we analysed its e...
متن کاملA multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
OBJECTIVES To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA). METHODS A multicentre, randomised, double-blind, placebo-controlled trial was conducted. The primary objective was to compare the efficacy of a 1-month treatment with anakinra (2 mg/kg subcutaneous daily, maximum 100 mg) with a placebo between two groups ...
متن کامل